Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>AcelRx Pharmaceuticals (<strong>ACRX</strong>) will present data from the DSUVIA (sufentanil sublingual tablet, 30 mcg) clinical program at two upcoming medical meetings. On March 16, 2017, during the annual meeting of the American Academy of Pain Medicine, AcelRx will present a poster from SAP101 comparing the pharmacokinetics of DSUVIA to that of an intravenous (IV) infusion of Sufenta (sufentanil citrate injection, 30 mcg). On March 21, 2017, AcelRx will present safety and efficacy findings from SAP302 during the International Symposium on Intensive Care and Emergency Medicine being held in Brussels. SAP302 was an open-label Phase 3 trial conducted in 76 adult patients who present to the emergency department with moderate-to-severe acute pain associated with trauma or injury.</li><li>Glaukos Corporation (<strong>GKOS</strong>) announced that the Current Procedural Terminology Editorial Panel of the American Medical Association has granted five-year extensions to three Category III CPT codes that describe insertion of aqueous drainage devices into the anterior chamber of the eye using Micro-Invasive Glaucoma Surgery.</li><li>Companhia Paranaense de Energia (<strong>ELP</strong>) hereby informs that the Executive Board of the Brazilian Electricity Regulatory Agency — Aneel denied Copel Geração e Transmissão S.A.'s request to reconsider order 1580/2016, which rejected the administrative application for the recognition of exclusions of liability for the delay in the Colíder Hydroelectric Power Plant implementation schedule and the exemption of charges and regulatory, contractual or commercial penalties. Considering that the plant's startup schedule was impacted by government actions and force majeure events that occurred during the project's implementation, the co will take this matter to court with the certainty that Agency's decision will be overturned. The startup of the first generation unit is scheduled for Dec 2017 and the third and last generation unit is scheduled to begin operating in April 2018. The co also states that Copel GeT participated in the offer to reduce the Electricity Trading Contracts in the Regulated Environment — CCEARs related to the annual processing of the Mechanism for Compensation of Surpluses and Deficits — MCSD of New Energy for the product from Jan 1 to Dec 2017 and, as a result, the Colíder HPP obtained a full reduction of its contracts (125 average-MW) for 2017.</li></ul></td> </tr></table>"